A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL.
The file type is application/pdf.
Tofacitinib as a Therapeutic Option in the Treatment of Refractory Scleritis: A Case Report
2021
JOURNAL OF CASE REPORTS AND STUDIES
Preserved Fulltext
This was a 50-year-old patient with recurrent bilateral nodular anterior scleritis refractory to several treatments, including immunosuppressants and anti Tnfα. She was assessed for the different causes of immune-mediated and infectious diseases, but nothing was found. Tofacitinib was started 5 mg twice a day, which led to the spacing of crises until their total disappearance. At present, the patient has been crisis-free for nine months. In conclusion, the use of Janus Kinase inhibitor
doi:10.15744/2348-9820.9.104
fatcat:6cq2tde5gbgithyv3etkxwoevu